VIRX - Viracta Therapeutics, Inc. Stock Price, Fair Value and News

0.81USD0.00 (0.00%)Delayed

Market Summary

USD0.810.00

Delayed

0.00%

VIRX Stock Price

View Fullscreen

VIRX RSI Chart

VIRX Valuation

Market Cap

31.8M

Price/Earnings (Trailing)

-0.66

Price/Sales (Trailing)

10.4

Price/Free Cashflow

-0.87

VIRX Price/Sales (Trailing)

VIRX Profitability

Return on Equity

-433.12%

Return on Assets

-116.1%

Free Cashflow Yield

-114.86%

VIRX Fundamentals

VIRX Revenue

Revenue (TTM)

3.1M

Rev. Growth (Yr)

-32.57%

Rev. Growth (Qtr)

-21.33%

VIRX Earnings

Earnings (TTM)

-48.0M

Earnings Growth (Yr)

25.13%

Earnings Growth (Qtr)

33.59%

Breaking Down VIRX Revenue

Last 7 days

6.6%

Last 30 days

-13.8%

Last 90 days

19.1%

Trailing 12 Months

-58.0%

How does VIRX drawdown profile look like?

VIRX Financial Health

Current Ratio

1.35

VIRX Investor Care

Shares Dilution (1Y)

2.24%

Diluted EPS (TTM)

-1.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.1M	0	0	0
2023	2.0M	2.9M	3.2M	3.3M
2022	42.0K	80.0K	544.0K	1.2M
2021	45.5K	43.0K	40.5K	38.0K
2020	58.0K	54.6K	51.3K	48.0K
2019	0	0	0	61.3K
2018	237.0K	237.0K	237.0K	237.0K
2017	2.6M	2.0M	1.3M	669.0K
2016	2.8M	2.6M	2.5M	2.5M
2015	4.6M	3.5M	3.3M	3.1M
2014	8.0M	8.0M	6.8M	5.7M
2013	5.7M	6.2M	8.0M	8.0M
2012	0	2.5M	2.8M	3.8M
2011	4.5M	4.6M	4.8M	5.0M
2010	0	3.9M	4.1M	4.3M
2009	0	0	0	3.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Viracta Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 27, 2024	chevallard daniel r.	sold	-2,493	0.7322	-3,405	cfo and coo
Feb 25, 2024	royston ivor	acquired	-	-	25,219	-
Feb 25, 2024	pomerantz roger	acquired	-	-	9,034	-
Feb 25, 2024	chevallard daniel r.	acquired	-	-	6,889	cfo and coo
Dec 01, 2023	rothera mark	bought	23,627	0.4932	47,906	president and ceo
Nov 30, 2023	rothera mark	bought	25,734	0.494	52,094	president and ceo
Nov 28, 2023	chevallard daniel r.	sold	-1,860	0.5	-3,720	cfo and coo
Nov 25, 2023	pomerantz roger	acquired	-	-	9,034	-
Nov 25, 2023	chevallard daniel r.	acquired	-	-	6,889	cfo and coo
Nov 25, 2023	royston ivor	acquired	-	-	25,219	-

Which funds bought or sold VIRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	added	35.12	70,593	120,377	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	52.17	7,920	12,516	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	1,000	3,000	-%
May 15, 2024	Samsara BioCapital, LLC	unchanged	-	310,369	703,503	0.11%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-20,576	-	-%
May 15, 2024	HOYLECOHEN, LLC	unchanged	-	6,300	14,280	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-36.5	1,088	9,067	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-8,911	-	-%
May 15, 2024	Laurion Capital Management LP	reduced	-25.32	107,928	428,835	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	33,300	75,480	-%

Are Funds Buying or Selling VIRX?

Are funds buying VIRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VIRX

No. of Funds

Unveiling Viracta Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	forward ventures v lp	6.65%	2,567,522	SC 13G
Feb 14, 2023	biotechnology value fund l p	5.2%	1,992,047	SC 13G/A
Jan 10, 2023	schindel yair chaim	14.03%	5,359,372	SC 13D/A
Jul 08, 2022	blackrock inc.	1.4%	542,431	SC 13G
Feb 15, 2022	lytton laurence w	0.7%	255,876	SC 13G/A
Feb 14, 2022	biotechnology value fund l p	4.9%	1,828,558	SC 13G/A
Feb 14, 2022	aisling capital iv, lp	0.77%	288,571	SC 13G
Feb 09, 2022	forward ventures v lp	7.14%	2,664,790	SC 13G/A
Feb 04, 2022	blackrock inc.	6.3%	2,368,918	SC 13G

Recent SEC filings of Viracta Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	3	Insider Trading
May 16, 2024	4	Insider Trading
May 14, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 09, 2024	8-K	Current Report
Mar 22, 2024	3	Insider Trading

Peers (Alternatives to Viracta Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Viracta Therapeutics, Inc. News

Latest updates

Viracta Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4	2018Q3	2018Q2
Revenue	-21.3%	592,000	752,500	827,000	887,000	878,000	637,000	474,000	50,000	10,000	10,000	10,000	12,000	6,000	41,000	76,000	4,000	40,000	20,000	-	-	-
Costs and Expenses	-	-	-	-	-	-	-	266,667	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	2.3%	13,876,000	13,561,000	12,475,000	12,450,000	12,207,000	11,574,000	18,078,000	10,505,000	10,432,000	11,318,000	14,799,000	9,317,000	92,342,000	6,126,000	3,992,000	4,240,000	4,457,000	-5,875,680	5,760,000	6,277,000	6,582,000
S&GA Expenses	-100.0%	-	4,154,000	4,317,000	4,253,000	4,600,000	4,871,000	10,939,000	4,181,000	4,336,000	4,015,000	3,711,000	3,871,000	3,840,000	2,571,000	887,000	879,000	1,011,000	-4,275,035	2,459,000	2,690,000	2,824,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,340,201	2,157,000	4,281,000	3,690,000	-1,600,645	3,301,000	3,587,000	3,758,000
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-683	-580	-505	-446	-340	-263	-144	-373	-107	-	-
Interest Expenses	-10.4%	851,000	949,500	953,000	921,000	880,000	187,000	139,000	127,000	124,000	139,000	125,000	122,000	105,000	117,500	66,000	65,000	-	-400,183	295,000	291,000	287,000
EBT Margin	-	-	-	-	-	-	-	-	-	-	-	-695	-588	-509	-449	-342	-265	-145	-380	-112	-	-
Net Income	33.6%	-9,141,000	-13,765,000	-12,600,000	-12,484,000	-12,209,000	-10,326,000	-17,743,000	-10,582,000	-10,546,000	-11,447,000	-14,914,000	-9,170,000	-79,231,000	-6,285,000	-4,079,000	-4,236,000	-4,417,000	4,484,123	-5,997,000	-6,505,000	-6,840,000
Net Income Margin	-2.8%	-15.69	-15.27	-14.75	-18.35	-24.94	-42.01	-92.50	-593	-1,097	-3,020	-2,706	-2,296	-	-	-	-	-	-	-	-	-
Free Cashflow	21.7%	-7,849,000	-10,027,000	-10,484,000	-7,990,000	-11,340,000	-7,903,000	-7,158,000	-9,053,000	-11,382,000	-7,230,000	-7,826,000	-6,593,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-27.1%	41,334	56,692	66,437	76,859	85,781	95,991	82,198	89,155	98,387	108,552	116,540	128,679	136,209	48,305	28,033	25,506	31,487	18,444	41,610	21,044	27,754
Current Assets	-25.5%	40,952	54,964	64,442	74,555	83,415	93,747	79,680	86,365	95,373	105,273	113,015	125,142	132,304	47,199	27,624	24,865	30,709	18,299	40,549	19,842	26,410
Cash Equivalents	-2.1%	12,062	12,317	12,856	14,293	18,099	36,773	23,472	81,583	92,199	103,554	110,983	122,721	129,181	47,089	11,906	17,653	19,974	18,218	19,733	9,797	24,811
Net PPE	-14.2%	163	190	218	296	125	148	184	220	210	242	258	41.00	40.00	44.00	-	-	1.00	2.00	5.00	7.00	9.00
Liabilities	-21.2%	30,254	38,373	36,429	36,077	35,483	34,888	-	-	-	-	-	-	-	3,310	3,567	9,400	9,401	9,697	9,316	9,305	10,668
Current Liabilities	-21.2%	30,254	38,373	36,429	15,213	11,655	10,011	9,387	7,221	7,766	9,084	7,161	6,953	6,265	6,284	3,567	9,400	9,261	2,394	8,894	8,743	9,975
Long Term Debt	-	-	-	-	20,791	22,834	24,877	4,869	4,860	4,841	4,819	5,026	4,155	4,633	4,155	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	833	573	1,031	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	20,791	22,834	24,877	4,869	4,860	4,841	4,819	5,026	4,155	4,633	4,155	-	-	-	-	-	-	-
Shareholder's Equity	-39.5%	11,080	18,319	30,008	40,782	51,113	61,103	67,812	77,003	85,605	94,371	103,975	117,097	124,744	19,937	24,466	16,106	22,086	27,543	32,294	11,739	17,086
Retained Earnings	-3.5%	-275,100	-265,900	-252,167	-239,567	-227,100	-214,874	-204,500	-186,800	-176,223	-165,677	-154,200	-139,300	-130,146	-50,915	-699,603	-694,965	-688,575	-31,897	-677,512	-671,570	-665,329
Additional Paid-In Capital	0.7%	280,703	278,786	276,784	275,008	272,827	270,699	267,103	258,352	256,372	254,592	252,749	250,957	249,434	4,714	718,522	699,291	698,881	3,515	698,032	676,189	656,761
Shares Outstanding	0.5%	39,272	39,094	38,625	38,580	38,411	38,345	37,614	37,568	37,536	37,425	29,996	37,221	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	50,200	-	-	-	145,700	-	-	-	312,600	-	-	-	28,910	-	-	-	46,416	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	21.7%	-7,849	-10,027	-10,535	-7,990	-11,340	-7,903	-7,157	-9,034	-11,363	-7,211	-7,598	-6,593	2,551	-4,541	-4,255	-3,600	-3,658	8,057	-5,430	-6,894	-6,113
Share Based Compensation	3.0%	1,837	1,784	1,776	1,977	2,112	2,174	7,646	1,956	1,772	1,808	1,704	1,386	644	137	100	68.00	-	-648	465	394	417
Cashflow From Investing	53.1%	14,192	9,270	9,098	3,980	-7,350	-203	-52,057	-1,606	-	-19.00	-4,228	-5.00	17,143	-	-5.00	-50.00	-	13,080	-10,694	-	-
Cashflow From Financing	-3126.6%	-6,598	218	-	204	16.00	21,407	1,103	24.00	8.00	-199	88.00	138	62,398	39,724	4,992	264	-	-18,469	26,060	-234	17,228

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VIRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 9,956	$ 7,607
General and administrative	3,920	4,600
Total operating expenses	13,876	12,207
Loss from operations	(13,876)	(12,207)
Other income (expense):
Interest income	592	878
Interest expense	(858)	(880)
Realized gain on investments	1	0
Other income	5,000	0
Total other income (expense)	4,735	(2)
Net loss	(9,141)	(12,209)
Unrealized gain (loss) on short-term investments	(15)	91
Comprehensive loss	$ (9,156)	$ (12,118)
Net loss per share of common stock, basic	$ (0.23)	$ (0.32)
Net loss per share of common stock, diluted	$ (0.23)	$ (0.32)
Weighted-average shares used to compute basic net loss per share	39,323,964	38,458,837
Weighted-average shares used to compute diluted net loss per share	39,323,964	38,458,837

VIRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 12,062	$ 12,317
Short-term investments	27,504	41,374
Prepaid expenses and other current assets	1,386	1,273
Total current assets	40,952	54,964
Property and equipment, net	163	190
Operating lease right-of-use asset	175	274
Other assets	44	1,264
Total assets	41,334	56,692
Current Liabilities:
Accounts payable	2,412	2,441
Accrued expenses	8,985	10,376
Operating lease liabilities	179	282
Debt, net	18,678	25,274
Total current liabilities	30,254	38,373
Total liabilities	30,254	38,373
Commitments and contingencies (Note 7)
Stockholders' equity:
Convertible preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024; 10,248 shares issued and outstanding as of March 31, 2024 and December 31, 2023	5,452	5,452
Common stock, $0.0001 par value; 400,000,000 shares authorized; 39,272,434 and 39,093,509 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	280,703	278,786
Accumulated other comprehensive income (loss)	(6)	9
Accumulated deficit	(275,073)	(265,932)
Total stockholders' equity	11,080	18,319
Total liabilities and stockholders' equity	$ 41,334	$ 56,692

About Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

CEO	Mr. Mark Andrew Rothera
WEBSITE	viracta.com
INDUSTRY	Biotechnology
EMPLOYEES	41

Viracta Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Viracta Therapeutics, Inc.? What does VIRX stand for in stocks?

VIRX is the stock ticker symbol of Viracta Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viracta Therapeutics, Inc. (VIRX)?

As of Fri May 17 2024, market cap of Viracta Therapeutics, Inc. is 31.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIRX stock?

You can check VIRX's fair value in chart for subscribers.

What is the fair value of VIRX stock?

You can check VIRX's fair value in chart for subscribers. The fair value of Viracta Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viracta Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viracta Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VIRX is over valued or under valued. Whether Viracta Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Viracta Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIRX.

What is Viracta Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VIRX's PE ratio (Price to Earnings) is -0.66 and Price to Sales (PS) ratio is 10.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Viracta Therapeutics, Inc.'s stock?

In the past 10 years, Viracta Therapeutics, Inc. has provided -0.445 (multiply by 100 for percentage) rate of return.